Nutraceuticals
Back

Products

100 years of botanical excellence mean a wide range of botanical derivatives. Search for them.

Go to section
Back

Things to watch

Go to section
Back

Media and news

Here is the right place where you can read all the latest news and information about Indena’s world.

See through science

See through science

Quercefit®

Quercefit®

Scroll to see more

Peer-reviewed science on Quercefit®

Is this the beginning of a natural approach?1

The administration of Quercefit® for a three-month period has been correlated with a favorable modulation of the body’s physiological response to symptomatic Covid-19 (Figures 1, 2).

This stems from the results of a single-center, prospective, randomized, controlled cohort study that enrolled a total of 120 healthcare workers (not vaccinated and taking all virus containment measures) randomized into two groups (60 subjects each), supplementing respectively with Quercefit® (250 mg twice a day) or a placebo.

quercefit_sts-02_new

Figure 1: Survival without Covid-19 during follow-up time between groups.

quercefit_sts-01_new

Figure 2: Conditions assessed by NEWS in subjects exposed to Covid-19.

Help from nature2,3,4

The administration of Quercefit® as diet supplementation showed positive effects in another study: of the 5 subjects who contracted Covid-19, there was only 1 out of the 60 in the quercetin Phytosome® group and 4 out of 60 in the control group. Complete clinical remission was recorded at 7 and 15 days in the supplementation and placebo groups, respectively.

These data were obtained during a prospective, randomized, controlled, open-label study in which 152 subjects were enrolled and randomized in two groups treated respectively with standard care or standard care plus Quercefit® (500 mg twice a day).2

A second clinical trial confirmed the benefits of diet supplementation with quercetin. The results showed that subjects who received Quercefit® (n= 21) had better outcomes compared to the ones receiving standard care.3

All data confirmed for Quercefit®4

These data were validated thanks to the completion of an initial clinical study now extended to 100 Sars-CoV-2-positive subjects that received standard care either alone or with Quercefit® as add-on supplementation (500 mg 3 times a day for the first week; 2 times a day for the second). The results confirmed that subjects who received standard care plus Quercefit® recovered faster and were in better health compared to the control group.4

Indeed, 68% of the subjects who received quercetin supplementation recovered faster from the virus (within one week), compared to 24% in the control group (Figure 3). Moreover, individuals following the Quercefit® regimen had weaker symptoms and showed a better biomarker profile (reduction of LDH) within a week. These data are also complemented by the confirmation of the product’s good tolerability.4

quercefit_sts-10

Figure 3: Subjects’ follow-up RT-PCR COVID-19 test results in the two groups.

Improvements in allergy-related discomforts and quality of life5

Repeated oral intake of a Quercefit®-containing supplement for 4 weeks has been shown to reduce allergy-related symptoms such as eye itching, sneezing, nasal discharge and sleep disorders compared to the placebo group (n=66).5

Moreover, the treated group also experienced improved quality of life, as reported in the chart below (Figure 4). 5

quercefit_sts-06

Figure 4: Total score of the Japanese Rhino-conjunctivitis Quality of Life Questionnaire in the two groups, before starting supplementation (baseline), and 2 and 4 weeks later. Graphic representation of ref.1 table III.

Allergic conjunctivitis? Try Quercefit® as complementary treatment6

Confirming its beneficial role for ocular allergy-related disorders, a study performed on adults affected by allergic conjunctivitis showed that Quercefit® may potentially be the perfect natural aid to avoid clinical worsening. In particular, an analysis on 15 subjects after 15 days of supplementation (250 mg, twice a day) highlighted significant improvements in terms of Total Ocular Symptoms Score (TOSS) (Figure 5).6

quercefit_sts-08

Figure 5: TOSS score before and after 15 days of Quercefit® supplementation.

Where it helps: allergy-prone subjects7

Quercefit® shows a potential promising effect during allergy season. A further study confirms that after 30 days, administration optimizes general wellbeing in allergy-prone subjects and modulates rhinitis, in addition to reducing the frequency of intermittent discomforts up to 50% during the day and up to 70% during the night.7

Prompt wellbeing restoration for injured eyes8

A series of 8 case studies have confirmed that Quercefit® can be the perfect ally for eye health, during topical antibiotic therapy on damaged ocular tissues (Figure 6).

quercefit_sts-09

Figure 6: Corneal condition following misuse of soft daily contact lenses, before (a) and after (b) supplementation.

Straight to the point9

Quercefit® provides an optimized quercetin solubility, proving up to 20-fold more bioavailable than unformulated quercetin, remaining in line with a diet rich in vegetables and fruits. Therefore, it can be used at lower dosages, while still offering the benefits of a quercetin full serving.

According to a trial on 12 participants (aged 18-50) administered with one oral dose of either 500 mg unformulated quercetin, 250 mg of Quercefit® or 500 mg of Quercefit®, Quercefit® optimizes quercetin plasma levels (Figure 7).

quercefit-02-int

Figure 7: Time-evolution of quercetin plasma concentrations (ng/ml) after oral administration of unformulated quercetin (red), Quercefit® 250 mg (gray) and Quercefit® 500 mg (blue).

Where it makes the difference: sports nutrition10

In a trial conducted on 48 non-professional triathlon athletes, Quercefit® showed positive effects on training and performance: the group administered with Quercefit® ran faster (-11.3% time from start to finish line, compared to -3.9% in the control group).

In addition, post-run muscular discomfort, cramps and recovery time all improved with Quercefit®, and oxidative stress was balanced (Figure 8).

quercefit-01

Figure 8: Plasma-free radical (PFR) units in the group administered with Quercefit® and in the control group.

BIBLIOGRAPHY
1Rondanelli M. et al.; Life (2022).
2Di Pierro F. et al.; Int J Gen Med 14 (2021):2359.
3Di Pierro F. et al.; Int J Gen Med 14 (2021):2807-2816.
4Di Pierro F. er al; Frontiers in Pharmacology (2023).
5Yamada, S. et al. European review for medical and pharmacological sciences (2022) 4331–4345.
6 Mazzolani et al.; Austin of allergy (2022).
7Cesarone, M. R., et al.; Minerva medica (2019).
8Mazzolani et al.; International Journal of Case Studies in Clinical Research (2022); Volume 6 Issue 3: 10-19.
9Riva A. et al.; Eur J Drug Metab Pharmacokinet (2018).
10Riva A. et al.; Minerva Medica (2018); 109(4):285-9.

Indena - Science is our nature

Sorry, our website doesn't support IE11 and older versions

For a better experience try a modern browser:

Indena

Indena

This is a private file, to request the download of this resource, please fullfill the fields below.